John Overdeck’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $72K | Sell |
54,947
-33,638
| -38% | -$46.5K | ﹤0.01% | 4924 |
|
|
2026
Q1 | $140K | Sell |
88,585
-177,000
| -67% | -$298K | ﹤0.01% | 4342 |
|
|
2025
Q4 | $444K | Sell |
265,585
-88,762
| -25% | -$154K | ﹤0.01% | 3380 |
|
|
2025
Q3 | $599K | Buy |
354,347
+36,370
| +11% | +$43K | ﹤0.01% | 2896 |
|
|
2025
Q2 | $289K | Sell |
317,977
-162,446
| -34% | -$96.4K | ﹤0.01% | 2806 |
|
|
2025
Q1 | $217K | Buy |
480,423
+178,879
| +59% | +$105K | ﹤0.01% | 2828 |
|
|
2024
Q4 | $152K | Buy |
+301,544
| New | +$221K | ﹤0.01% | 2914 |
|
|
2023
Q3 | – | Sell |
-81,816
| Closed | -$115K | – | 3094 |
|
|
2023
Q2 | $115K | Buy |
81,816
+56,510
| +223% | +$78.1K | ﹤0.01% | 2734 |
|
|
2023
Q1 | $38K | Sell |
25,306
-5,356
| -17% | -$7.48K | ﹤0.01% | 2788 |
|
|
2022
Q4 | $35.9K | Buy |
+30,662
| New | +$38.6K | ﹤0.01% | 2628 |
|
|
2022
Q1 | – | Sell |
-540,824
| Closed | -$1.32M | – | 3553 |
|
|
2021
Q4 | $1.32M | Sell |
540,824
-39,964
| -7% | -$93.5K | ﹤0.01% | 2304 |
|
|
2021
Q3 | $1.46M | Sell |
580,788
-733,779
| -56% | -$1.88M | ﹤0.01% | 2268 |
|
|
2021
Q2 | $3.75M | Buy |
1,314,567
+60,036
| +5% | +$155K | 0.01% | 1379 |
|
|
2021
Q1 | $2.95M | Buy |
1,254,531
+707,316
| +129% | +$1.7M | 0.01% | 1399 |
|
|
2020
Q4 | $963K | Buy |
547,215
+337,210
| +161% | +$472K | ﹤0.01% | 2041 |
|
|
2020
Q3 | $197K | Sell |
210,005
-118,936
| -36% | -$105K | ﹤0.01% | 2824 |
|
|
2020
Q2 | $286K | Buy |
328,941
+166,308
| +102% | +$146K | ﹤0.01% | 2408 |
|
|
2020
Q1 | $135K | Sell |
162,633
-191,072
| -54% | -$190K | ﹤0.01% | 2777 |
|
|
2019
Q4 | $315K | Buy |
353,705
+20,610
| +6% | +$17.2K | ﹤0.01% | 3158 |
|
|
2019
Q3 | $326K | Sell |
333,095
-32,345
| -9% | -$33.5K | ﹤0.01% | 2907 |
|
|
2019
Q2 | $402K | Sell |
365,440
-80,134
| -18% | -$92.3K | ﹤0.01% | 2661 |
|
|
2019
Q1 | $584K | Sell |
445,574
-84,403
| -16% | -$105K | ﹤0.01% | 2179 |
|
|
2018
Q4 | $484K | Buy |
529,977
+364,401
| +220% | +$558K | ﹤0.01% | 2125 |
|
|
2018
Q3 | $340K | Sell |
165,576
-37,419
| -18% | -$78.6K | ﹤0.01% | 2693 |
|
|
2018
Q2 | $366K | Buy |
202,995
+73,230
| +56% | +$147K | ﹤0.01% | 2821 |
|
|
2018
Q1 | $305K | Sell |
129,765
-200,836
| -61% | -$471K | ﹤0.01% | 2769 |
|
|
2017
Q4 | $622K | Buy |
330,601
+182,218
| +123% | +$398K | ﹤0.01% | 2287 |
|
|
2017
Q3 | $369K | Sell |
148,383
-9,302
| -6% | -$23.1K | ﹤0.01% | 2317 |
|
|
2017
Q2 | $435K | Buy |
+157,685
| New | +$441K | ﹤0.01% | 2429 |
|
|
2017
Q1 | – | Sell |
-75,592
| Closed | -$239K | – | 3121 |
|
|
2016
Q4 | $239K | Buy |
75,592
+35,150
| +87% | +$108K | ﹤0.01% | 2860 |
|
|
2016
Q3 | $138K | Buy |
+40,442
| New | +$112K | ﹤0.01% | 3008 |
|
|
2015
Q3 | – | Sell |
-79,122
| Closed | -$232K | – | 2476 |
|
|
2015
Q2 | $232K | Buy |
+79,122
| New | +$307K | ﹤0.01% | 2552 |
|
Other funds holding LCTX
BC
DC
RA
John Overdeck's LCTX Position: Q2 2026 in Review
John Overdeck reduced its Lineage Cell Therapeutics (LCTX) stake by 38% in Q2 2026, selling an estimated $46.5K and leaving 54,947 shares worth $72K. The position accounts for ﹤0.01% of the portfolio, ranked #4924.
John Overdeck first reported a position in LCTX in Q2 2015 and has held it in 32 quarters since. The position peaked at $3.75M in Q2 2021. 131 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.
- John Overdeck held 54,947 shares of Lineage Cell Therapeutics worth $72K as of Q2 2026.
- John Overdeck sold 33,638 Lineage Cell Therapeutics shares in Q2 2026, an estimated $46.5K.
- Lineage Cell Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4924 holding.
- John Overdeck first reported a position in Lineage Cell Therapeutics in Q2 2015 and has held it in 32 quarters since.
- John Overdeck's Lineage Cell Therapeutics position peaked at $3.75M in Q2 2021.
- 131 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.